Hevascol

Hevascol is a prescription‑only iodinated contrast agent whose active ingredient is ethyl esters of iodised fatty acids derived from poppyseed oil. The product’s strength and dosage form are not publicly disclosed, and it is supplied for intra‑arterial and intralymphatic administration during clinical procedures in the European market. Hevascol is classified as a diagnostic imaging agent used to enhance radiographic visibility of vascular and lymphatic structures.

Hevascol is employed as an iodinated contrast medium to improve the visualization of anatomical structures during various imaging examinations.

- Intra‑arterial angiography for detailed arterial mapping - Intralymphatic lymphography to assess the lymphatic system - Contrast‑enhanced CT or fluoroscopy when high iodine density is required - Pre‑procedural imaging in interventional radiology to delineate vessels - Evaluation of vascular grafts or stents for patency - Research settings involving vascular permeability studies

Adverse reactions to Hevascol are generally related to its iodine content and the physical properties of the contrast medium.

Common: - Mild warmth or flushing at the injection site - Transient nausea or vomiting - Headache or dizziness - Temporary increase in serum creatinine in susceptible patients - Metallic taste in the mouth - Mild itching or urticaria

Serious: - Acute hypersensitivity or anaphylactoid reactions - Severe renal impairment or contrast‑induced nephropathy - Pulmonary edema or respiratory distress - Cardiac arrhythmias or hypotension - Thrombosis at the injection site - Severe hypertension

Before administering Hevascol, clinicians should evaluate patient history and clinical status to minimize the risk of adverse events.

- Assess renal function; avoid use in patients with severe renal insufficiency - Review history of iodine allergy or prior contrast reactions - Ensure adequate hydration before and after the procedure - Use the lowest effective volume and concentration - Monitor vital signs during intra‑arterial injection - Consider alternative imaging in pregnant or lactating women - Adjust dose in elderly patients with comorbidities

Hevascol may interact with other agents that affect renal function, hemodynamics, or immune response.

Avoid: - Concurrent use of nephrotoxic drugs such as aminoglycosides or NSAIDs - High‑dose iodinated contrast agents administered within 24 hours - Angiotensin‑converting enzyme inhibitors or ARBs in patients with borderline renal function - Radioactive iodine therapy scheduled within a week

Use with caution: - Beta‑blockers in patients prone to hypotension - Diuretics that may alter fluid balance - Antihistamines or corticosteroids when pre‑medicating for contrast allergy